Why Eli Lilly Stock Popped Today

Group 1 - Eli Lilly's stock rose by 2.6% despite a market downturn, driven by two positive announcements [1] - The company plans to acquire Organovo's FXR program, including the drug FXR314, aimed at treating ulcerative colitis and metabolic dysfunction-associated steatohepatitis (MASH) [1][3] - Lilly will make an upfront payment and milestone payments to Organovo as FXR314 achieves key regulatory and commercial milestones, acquiring all commercial and intellectual property rights for worldwide development [3] Group 2 - Lilly announced a price cut for its Zepbound (tirzepatide) GLP-1 weight loss drug, with the 5 mg dose reduced to $349 per month and the 7.5 mg and 10 mg doses priced at$499 per month [2][5] - The pricing strategy for Zepbound is designed to enhance its attractiveness compared to competing diet drugs from Novo Nordisk and Hims & Hers Health, aiming to increase market share [4]